| The global lateral flow assays market, valued at $10.8 billion in 2023, is expected to reach $16.8 billion by 2029, growing at a CAGR of 7.6%. This growth is driven by the rising adoption of kits & reagents and lateral flow assay readers for various applications, including infectious disease testing, veterinary diagnostics, and drug abuse testing. However, challenges such as qualitative detection limitations and variability in results may hinder market growth. The increase in eye disorders like diabetic retinopathy and cataracts is a significant driver, while the rising adoption of refurbished equipment presents a restraint. Opportunities exist in the low adoption of phacoemulsification devices and premium IOLs in emerging regions. North America holds the largest market share, with significant investments in ophthalmic technology, while the Asia Pacific is the fastest-growing region. Key players include Abbott, Roche, Danaher Corporation and Siemens Healthineers. Recent developments include new authorizations and product launches by QuidelOrtho, Abbott, and Roche. |
